Braftovi® (encorafenib) – New indication
April 8, 2020 - Pfizer announced the FDA approval of Braftovi (encorafenib), in combination with Erbitux® (cetuximab), for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
Top